-- Presentation to be webcast on www.exelixis.com
--
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 4, 2016--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will provide
an overview of the company at the Leerink Partners Global Healthcare
Conference taking place February 10-11 in New York, New York. The
Exelixis presentation is scheduled for 11:05 AM EST/8:05 AM PST on
Wednesday, February 10, 2016.
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be require to listen to the webcast. A replay will also be available at
the same location for 14 days.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine
kinases. Another Exelixis-discovered compound, COTELLIC™ (cobimetinib),
a selective inhibitor of MEK, has been approved in Switzerland, the
United States, and the European Union, and is being evaluated by Roche
and Genentech (a member of the Roche Group) in a broad development
program under a collaboration with Exelixis. For more information,
please visit the company’s website at www.exelixis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160204006558/en/
Source: Exelixis, Inc.
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
Investor Relations and Corporate
Communications
shubbard@exelixis.com
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com
